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Background: Tumor prostheses currently give the best short- and medium-term results for limb-salvage
reconstruction procedures in the treatment of bone tumors. However, in developing countries, the cost of a tumor
prosthesis is beyond the reach of much of the population. We report the use of autoclaved tumor-bearing bone in
10 patients, as an affordable alternative to the use of prostheses.
Methods: This is a case series of 10 patients (mean age 19 years) with osteosarcoma who were treated at our
hospital from 1998 to 2008, and followed up for a mean of 35 months (range 14 to 8). The femur was involved in
six cases, the humerus in three cases, and the ulna in one case. The mean length of the autoclaved bone was 150
mm (range 60–210).
Results: Bone union occurred in seven patients over an mean duration of 12 months (range 8–17). Three patients
had non-union. Two of these had associated implant failure, with one of them also developing chronic infection,
and the third is still being followed up. Two other patients had local recurrence.
Conclusion: The use of autoclaved tumor grafts provides an inexpensive limb-salvage option without sacrificing
appropriate oncologic principles. A painless and stable limb is achievable, and the use of this technique can be
further refined.Background
After many decades of limb-salvage surgery for bone
tumors, it seems clear that tumor prostheses give the
best results in terms of function and comparative pau-
city of complications, at least in the short and medium
term [1]. Most studies on tumor prostheses have been
carried out in centers located in wealthier countries, and
in poorer countries, these prostheses are simply not af-
fordable. According to the World Health Organization,
80% of the world’s population live in developing coun-
tries, thus the availability and affordability of these state-
of-the-art techniques for these populations is limited [2].
For example, in our own hospital, the cost of a pros-
thesis is equivalent to 2 years’ wages for the average pa-
tient. Thus, even though limb salvage is often possible,* Correspondence: klpan@fmhs.unimas.my
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reproduction in any medium, provided the oramputation is carried out because the patient is unable
to afford the alternative [1,3],.
In this study, we used autoclaved tumor-bearing bone
as an affordable alternative to a prosthesis, requiring
only the material and equipment used in fracture treat-
ment. For tumors in the upper limb, the autoclaved bone
acts as a spacer, whereas for the lower limb, it is used
mainly for fusion at the knee joint. Initial complication
rates of this technique are higher, but once union is
achieved, the function of the salvaged limb is acceptable
and achieves better results than with amputations of the
arm with loss of the hand or with above-knee amputa-
tions of the leg [4]. It also provides a stable lower limb ,
and avoids the common sequelae of loosening of a pros-
thesis [5].
Methods
This was a retrospective case series. From 1998 to 2008,
18 patients with primary malignant tumors involving the
limb bones were treated with wide excision and recon-
struction using the patients own bone tissue, which was. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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planted. The university research and ethics committee
approved the grant and methodology for the study.
Informed consent was obtained from the patients or par-
ents for publication and use of images. Of the eighteen
patients, four patients died within 1 year of surgery (two
as a result of rapidly progressing lung metastases and an-
other two from causes related to the complications of
chemotherapy), and another four patients were lost to fol-
low-up. These eight patients were excluded, leaving 10
patients (four male and six female patients; mean age 19
years, range 11–35), who were followed up for a mean of
35 months (range 14–80) (Table 1).
Nine patients had a primary malignant bone tumor (all
osteosarcomas) and one patient had a soft-tissue osteosar-
coma that had invaded the adjacent bone. Six tumors
involved the distal femur (Figure 1), three involved the
proximal humerus, and one involved the middle third of
the ulna. All 10 patients underwent staging with plain
radiographs, magnetic resonance imaging (MRI) scan (of
the whole bone to identify any skip metastasis), computed
tomography of the thorax, and a bone scan. Examination
of an incisional biopsy was used to confirm the diagnosis.
All cancers were high-grade and extra-compartmental
tumors. Treatment was started with three cycles of neoad-
juvant chemotherapy, with an interval of 3 weeks between
each cycle. For each cycle, patients were given cisplatin on
day 1, and adriamycin on days 1–3. Each cycle of chemo-
therapy was followed by another MRI assessment, andTable 1 Clinical and tumor characteristics, treatment, and foll
Patient Age/
gender
Diagnosis/ site Tumor size,
mm1
Surgery
1 14/F OS/distal femur 30/50/100 Knee fusion, IMN








50/110/150 Spacer, cement graft
rod, composite
5 17/F OS, distal femur 150/200 Knee fusion, IMN, pla
6 13/M OS/proximal
humerus
110 Spacer, cement graft
rod, composite
7 32/F OS/distal femur 100/60/70 Knee fusion, locking
plate
8 35/F Soft-tissue OS,
ulna
60/50/20 Plate
9 20/M OS/distal femur 110/90/70 Knee fusion, plate
10 23/M OS/distal femur 110/100/140 Knee fusion, locking
plate
Abbreviations: IMN, intramedullary nail; OS, osteosarcoma.
1Tumor size: anterior–posterior/width/length.
2Patient is still being followed up.surgery was scheduled when limb salvage was deemed
feasible.
During the surgery, wide excision was performed, and
the soft-tissue components were grossly removed. The
specimen was then heated in an autoclave at 120° C for 10
minutes. Upon removal from the autoclave, the remaining
soft tissue and joint cartilage were easily scraped off from
the surface of the bone, Any ‘new’ bone formed by the
tumor osteoblastic process had been softened by the auto-
claving procedure and this was also scraped off easily. The
specimen was then cleaned with normal saline and pre-
pared for reinsertion. The whole process was performed
under sterile conditions, with sterile wraps used for trans-
port between the surgical field and the autoclave.
The autoclaved bone was reinserted in the original
tumor bed, and held in place by plates or intramedullary
nails. For procedures involving the upper limb, bone ce-
ment was used as an added spacer in regions where the
tumor had destroyed the bone. The mean length of auto-
claved bone was 150 mm (range 6–21), and the margin of
normal bone removed beyond the tumor was 30mm. The
resection margin for the soft tissue was through normal-
appearing tissue, generally 10–20 mm beyond the tumor,
except in regions where vital neurovascular bundles abut-
ted the tumor. An intra-operative biopsy was taken of the
intramedullary marrow proximal or distal to the tumor.
Occasionally, biopsies were also taken from the tumor bed
in areas where the resection margin was deemed by the









180 80 Non-union, 31 Infection
210 14 14
80 15 8 Fracture, local
recurrence
80 14 10
te 200 66 Non-union, 42
170 42 11
180 25 9 Infection
60 55 15
190 19 17 Local recurrence
170 17 Non-union, 172
Figure 1 Patient 2: 14-year-old boy with osteosarcoma of the
distal femur. (A) Plain radiograph showing changes at the distal
femur. (B) Magnetic resonance imaging scan showing the
intramedullary extent of the tumor (180 mm). A further 30 mm was
resected proximally during surgery, making a total of 210 mm of
bone that was autoclaved and replaced. (C) Intra-operative
photograph showing the autoclaved tumor bone placed in its
original bed. (D) Post-operative radiograph showing fixation of the
autoclaved tumor bone with a long locking plate and a 3.5 dynamic
compression plate at the proximal junction. (E) Follow-up 14
months later; bone union and full weight-bearing without aids.
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ation, including evaluation of the percentage of necrosis.
Once the wounds had healed, patients were given an-
other three cycles of adjuvant chemotherapy. Patients with
tumors in the lower limb were allowed to ambulate with
crutches, starting from non-weight-bearing and graduated
partial weight-bearing, and progressing to full weight-
bearing over the subsequent months, after union was
ascertained from radiographs. Patients with tumors in the
arm used a triangular bandage for 6 weeks for limb sup-
port, after which they were encouraged to freely use the
limb as pain allowed.
Patients were initially followed up at intervals of 6 weeks
then every 3 months until 1.5 years after surgery, then,
every 6 months until 5 years after surgery, and then yearly
thereafter.
At each follow-up, plain radiographs (two views) were
taken, encompassing both the proximal and distal graft-
host junction (when this applied). All readings of the
radiographs in relation to union were done by the sameinvestigator (KLP). Union was judged to have taken
place when bridging callus was seen on three cortices.
However, this was not always easily visualized when the
junction was bridged by two plates or by a nail plus a
plate. In such instances, two cortices with bridging cal-
luses were accepted for union. For reconstructions with
two graft-host junctions, the time to union was the time
taken for both junctions to be united. In cases of lower
limb surgery with knee fusions, the distal junction (can-
cellous bone) always united first. Bone grafting was not
performed for patients with non-union.
Results
Union occurred in seven of the ten patients over a mean
duration of 12 months (range 8–17). Two patients had
non-union associated with implant failure; both under-
went an additional procedure (one received a plate and
one Ilizarov bone transport) which subsequently resulted
in union. Union had not been achieved in the final patient
at 17 months, and this patient is still being followed up.
Bone grafting was contemplated for this patient, but this
was not carried out because it was likely that the femoral
artery and vein were embedded in the mass of fibrous scar
tissue around the non-union site. Some skin had also been
removed with the tumor from the first surgery, and tight
skin coverage over the bone grafts may predispose to skin
necrosis.
In relation to complications, one patient (non-union of
the humerus) had a fracture through the autoclaved bone
in an area that was not reinforced by any metal, and this
also united with an added plate. One patient had an infec-
tion, which cleared up with antibiotics, debridement, and a
local medial gastrocnemius muscle rotation flap. Another
patient (with non-union), developed chronic osteomyelitis
and still had a discharging sinus at the most recent follow-
up. Two patients had local recurrence of the cancer: one
underwent radiotherapy and the other had an amputation.
All biopsies taken from suspected tumor-bed sites and
from the bone marrow proximal or distal to the resected
parts were clear of tumor cells.
Discussion
Most primary malignant tumors involving the limb bones
are surgically treated, either by amputations or limb salvage.
Limb salvage requires reconstituting the skeletal defect after
tumor resection. The main modes of reconstruction in the
lower limb have used resection arthrodesis, osteoarticular
allografts, or tumor prostheses [4].
It is generally accepted that tumor prostheses provide
the best results in relation to function and complications,
at least in the short and medium term [6,7]. However, they
are costly and require monitoring in the long term for
loosening, which may entail replacement with another
costly implant. At our hospital, each of these prostheses is
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grafts are affordable but require a nearby active bone bank
and the availability of appropriate bone parts and sizes.
Use of allografts also necessitates timely transport and
storage at the recipient center before surgery.
In less developed countries, many orthopedic surgeons
who seek to perform salvage on the lower limbs in these
patients have to fall back on resection arthrodesis, which
has been shown to be functionally superior to an above-
knee amputation [4]. When an amputation is the only
option offered, many patients and parents will not con-
sent to ablative surgery and will voluntarily discharge
themselves from hospital to seek traditional treatment.
There is thus a need to develop and refine methods such
as resection arthrodesis, which is affordable and, at the
same time, does not compromise the principles of treat-
ment of such patients.
In patients with high-grade osteosarcoma of the prox-
imal humerus, limb resection in lieu of a forequarter
amputation is widely accepted, especially when the
elbow and hand function can be preserved [8]. Pros-
theses or intercalary implants are an option. Allografts
or autografts (for example, fibula specimens) are often
used to bridge the gap, but large autografts will increase
donor site morbidity [9].
In the present study, by autoclaving and reusing the
patient’s own bone, we obviated the need to procure an
allograft. The fact that the bone fits the original defect is
an added advantage of the method. There is also no risk
of infection such as HIV or hepatitis from a donor bone.
Extracorporeal irradiation (instead of autoclaving) and
reimplantation has also been used in previous studies,
but this increases the intra-operative logistics and neces-
sitates the ready availability of the radiation oncologist
and radiotherapy machine at a specified time.
Pasteurization is an alternative that does not weaken the
bone to the same extent as with autoclaving [10]; it
requires the availability of a homeothermal heater to
maintain a temperature of 60°C for 30 minutes. Occa-
sionally, it may be found that the tumor has caused large
defects or destroyed the bone altogether; in such cases,
the defects can be filled or the part refashioned using
bone cement.
In our study, union was achieved in seven of the ten
patients after a mean duration of 12 months. Similar
studies have reported union in 11 out of 12 patients after
24 months [11] and in 11 out of 12 after 4.6 months
[12]. Chang et al. [13] reported union in 11 out of 14
patients (duration not reported, but in that study, a vas-
cularized bone graft was added to the autoclaved bone.
Two of the non-unions occurred in the femur at the
proximal graft-host junction. Both were spanned by intra-
medullary nails, which did not provide sufficient stability
for union, resulting in implant failure as well. We treatedone patient by the addition of a plate, and in the other pa-
tient, an Ilizarov transport fixator was used because the
patient also had an infection. Both bones subsequently
united. Having learnt from these cases, we now use a long
locking plate spanning both junctions, and add a second
four-hole compression plate at the proximal junction,
which provides a stronger and more stable construct. We
believe that the other important factor in non-union is the
vascularity of the overlying soft tissue, particularly the
muscle cover, especially at the graft-host junction.
We did not have problems with union in any of the
patients who had tumors of the upper limb. However,
one patient did sustain a fracture through the autoclaved
tumor bone that was not spanned by an implant. After
fixation with an additional plate, the fracture united,
even though one end of the fracture was part of the
autoclaved bone.
Two patients had deep infection. In one patient, the
infection cleared after antibiotics, debridement, and cov-
ering of the area with a gastrocnemius muscle local rota-
tion flap. We are now careful at the initial surgery to
cover all parts of the autoclaved bone with muscle be-
fore suturing the skin over it. In the distal femur, this is
usually achieved by releasing the sartorius muscle and
when necessary, by rotating the gastrocnemius muscle.
We treated the other patient with an infected non-union
by means of an Ilizarov fixator and bone transport. Al-
though we achieved union, we were not able to clear the
infection in this patient.
There were two patients with local recurrence. The re-
current nodules were clinically mobile and arose from
the soft tissue rather than from the autoclaved bone.
One patient was treated with radiotherapy and the other
underwent amputation.
Conclusion
The management of primary malignant bone tumors in
less developed countries is often a daunting task, strewn
with a long list of complications. Patients often present
late, by which time the tumors have grown to a large
size, and further delays are encountered in waiting for
investigations [14]. The final problem lies in reconstruc-
tion of the bone defect with affordable and available
means; for many patients at this point, amputation often
seems to be the only resort.
The use of autoclaved tumor grafts provides a limb-
salvage option that is inexpensive and independent of
external resources without sacrificing appropriate onco-
logic principles. A painless and stable limb is achievable
when the short- and medium-term complications can be
averted or surmounted.
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